Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.

@article{Perrino2014CurativePO,
  title={Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.},
  author={Elena Perrino and Martina Theresia Steiner and Nikolaus Krall and Gonçalo J L Bernardes and Francesca Pretto and Giulio Casi and Dario Neri},
  journal={Cancer research},
  year={2014},
  volume={74 9},
  pages={
          2569-78
        }
}
It is generally thought that the anticancer efficacy of antibody-drug conjugates (ADC) relies on their internalization by cancer cells. However, recent work on an ADC that targets fibronectin in the tumor microenvironment suggests this may not be necessary. The alternatively spliced extra domains A and B (EDA and EDB) of fibronectin offer appealing targets for ADC development, because the antigen is strongly expressed in many solid human tumors and nearly undetectable in normal tissues except… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 42 CITATIONS

Evolving Strategies for Target Selection for Antibody-Drug Conjugates

  • Pharmaceutical Research
  • 2015
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Chemotherapeutic drug delivery by tumoral extracellular matrix targeting.

  • Journal of controlled release : official journal of the Controlled Release Society
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 50 REFERENCES

Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients.

  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2013
VIEW 1 EXCERPT